Frontiers in Tuberculosis最新文献

筛选

英文中文

Innovative laboratory methods for improved tuberculosis diagnosis and drug-susceptibility testing 改进结核病诊断和药敏试验的创新实验室方法

Frontiers in Tuberculosis Pub Date : 2024-01-05 DOI: 10.3389/ftubr.2023.1295979

Nathan Mugenyi, Nelson Ssewante, J. Baruch Baluku, F. Bongomin, Mutuku Mukenya Irene, Alfred Andama, Pauline Byakika-Kibwika

{"title":"Innovative laboratory methods for improved tuberculosis diagnosis and drug-susceptibility testing","authors":"Nathan Mugenyi, Nelson Ssewante, J. Baruch Baluku, F. Bongomin, Mutuku Mukenya Irene, Alfred Andama, Pauline Byakika-Kibwika","doi":"10.3389/ftubr.2023.1295979","DOIUrl":"https://doi.org/10.3389/ftubr.2023.1295979","url":null,"abstract":"The laboratory plays a vital role in the diagnosis of all clinical forms of tuberculosis (TB), from microbiological confirmation of Mycobacterium tuberculosis to drug-susceptibility testing (DST) and treatment monitoring. For many decades, laboratory diagnosis of tuberculosis was based on conventional methods such as smear microscopy, and culture-based methods. However, Mycobacterium tuberculosis is a slow-growing organism, requiring 2–4 weeks or longer for cultures to yield results. Therefore, the evaluation of novel and rapid diagnostic methods has been a priority for research and development. In the beginning of 1990s, molecular-based diagnostics became widely available providing rapid detection, identification, and DST of M. tuberculosis. In this paper, we review some of the new diagnostic methods introduced in the clinical laboratory for the diagnosis of tuberculosis. With the global goal of ending TB as a public health challenge by 2030, enhancing diagnostic capabilities for latent and active TB, along with improving DST, would improve identification and management of cases, reducing transmission rates and curbing the spread of drug-resistant strains. These innovations promise to transform TB control efforts, bringing us closer to eradicating this persistent global health threat.","PeriodicalId":429644,"journal":{"name":"Frontiers in Tuberculosis","volume":"13 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139382847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute phase proteins and IP-10 in plasma for tuberculosis diagnosis 用于结核病诊断的血浆中的急性期蛋白和 IP-10

Frontiers in Tuberculosis Pub Date : 2023-11-29 DOI: 10.3389/ftubr.2023.1267221

B. Molina-Moya, R. Villar-Hernández, N. Ciobanu, B. Muriel-Moreno, A. Lacoma, A. Codreanu, I. Latorre, Daria Smalchuk, C. Prat-Aymerich, V. Crudu, K. Kontogianni, Luis E. Cuevas, José Domínguez

{"title":"Acute phase proteins and IP-10 in plasma for tuberculosis diagnosis","authors":"B. Molina-Moya, R. Villar-Hernández, N. Ciobanu, B. Muriel-Moreno, A. Lacoma, A. Codreanu, I. Latorre, Daria Smalchuk, C. Prat-Aymerich, V. Crudu, K. Kontogianni, Luis E. Cuevas, José Domínguez","doi":"10.3389/ftubr.2023.1267221","DOIUrl":"https://doi.org/10.3389/ftubr.2023.1267221","url":null,"abstract":"Tuberculosis (TB) is a leading cause of death from a single infectious agent, and triage tests based on biomarkers may help to improve the diagnosis. This study aims to determine whether C-reactive protein (CRP), interferon-γ-inducible protein 10 (IP-10), α1-acid glycoprotein (AGP), and α1-anti-trypsin (AAT) could be useful for a screening test in patients with presumptive TB disease.CRP, IP-10, AGP, and AAT were measured in plasma samples from 277 patients with presumptive TB disease in the Republic of Moldova in a prospective study.In general, the levels of all the biomarkers were higher in patients with TB than in the other groups (p < 0.05). Receiver operating characteristic curve analyses showed an area under the curve lower than 0.7 for all the biomarkers, and low correlations (Spearman's r < 0.6) were found between biomarkers.The levels of the tested biomarkers were different throughout the patient groups studied, but their suboptimal diagnostic performance either as individual biomarkers or in combination does not favor their use for triage testing.","PeriodicalId":429644,"journal":{"name":"Frontiers in Tuberculosis","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139214985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recognition and control of Mycobacterium tuberculosis-infected cells: from basics to the clinic: a NIAID/WGNV workshop report 2023 结核分枝杆菌感染细胞的识别与控制：从基础到临床：NIAID/WGNV 研讨会报告 2023

Frontiers in Tuberculosis Pub Date : 2023-11-15 DOI: 10.3389/ftubr.2023.1303505

Carly Young, Mbali N. Mkhonza, P. Ogongo

引用次数: 0